Skip to main content

Analysts’ Top Healthcare Picks: Serina Therapeutics (SER), Cybin (CYBN)

Tipranks - Tipranks - Sat Nov 15, 2025

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Serina Therapeutics (SER – Research Report) and Cybin (CYBN – Research Report) with bullish sentiments.

Meet Your ETF AI Analyst

Serina Therapeutics (SER)

In a report released today, Justin Walsh from JonesTrading reiterated a Buy rating on Serina Therapeutics, with a price target of $11.00. The company’s shares closed last Friday at $3.99, close to its 52-week low of $3.81.

According to TipRanks.com, Walsh is a 5-star analyst with an average return of 17.8% and a 36.3% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Radiopharm Theranostics Limited Sponsored ADR, Bioline RX Ltd Sponsored ADR, and Praxis Precision Medicines. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Serina Therapeutics with a $13.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Cybin (CYBN)

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Cybin, with a price target of $55.00. The company’s shares closed last Friday at $6.02.

According to TipRanks.com, Trucchio is a top 100 analyst with an average return of 34.8% and a 52.3% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Arrowhead Pharmaceuticals, and Alto Neuroscience, Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cybin with a $47.00 average price target.

Read More on SER:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).